Meridian Clinical Trials - Kimberly-Guede

Chris is a board-certified neurologist and physician-scientist focused on the development of novel treatments for neurodegenerative diseases. In 2010, he joined the department of Clinical Pharmacology at Merck Research Labs where he primarily focused on early clinical development, but had the experience of conducting a pivotal safety study for sugammadex (Bridion) which directly led to its approval. Chris has worked in startup biotechnology companies, from working on cell therapy at BlueRock, to neuroscience-focused Cerevel, and now at Enterin where he is Head of Medical and Clinical Development.

Speaker Details